Treatment Information

Back

Kidney (Renal) Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, New York, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:New York, New York
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Jan 2002

Description:

Patients: This Phase II study involved 26 patients with advanced renal cell carcinoma; 23 men and 3 women. The median age was 58. Prior treatments included nephrectomy (15 patients), immunotherapy (15 patients), and radiation therapy (4 patients).

Treatment: The treatment consisted of the drug thalidomide (thalomid), an anti-angiogenesis agent. (Angiogenesis refers to the creation of new blood vessels, which cancers require.)

Toxicity: Grade 3 toxicities included sinus brachycardia, thrombosis, neuropathy, vertigo, and dyspnea.

Results: No patient achieved a partial or complete response.

Support: The study was supported by Celgene Corp. This company markets thalidomide (thalomid).

Correspondence: Robert J. Motzer, MD




Back